Despite a parade of studies warning that treatment guidelines issued by professional medical societies fail to fully disclose potential financial conflicts, two new analyses report that the problem persists.

In one analysis, researchers found that 57 percent of 91 authors who developed 18 different guidelines for several big-selling medicines had financial conflicts, and 25 percent of the authors did not disclose a conflict in the guidelines or supplemental materials. The median undisclosed payment was $522, while the average was $17,000. Moreover, none of the guidelines were fully compliant with disclosure requirements issued by the National Academy of Medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy